Swerdlow SH, et al editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017.

Google Scholar 

Lymphoma Study Group of Japanese Pathologists. The world health organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int. 2000;50(9):696–702.

Article  Google Scholar 

Hans CP, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–82.

Article  CAS  PubMed  Google Scholar 

Davies A, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(5):649–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Younes A, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol. 2019;37(15):1285–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nowakowski GS, et al. ROBUST: a phase III study of Lenalidomide plus R-CHOP VERSUS PLACEBO PLUS R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carbone PP, et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res. 1971;31(11):1860–1.

CAS  PubMed  Google Scholar 

International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329(14):987–94.

Article  Google Scholar 

Zhou Z, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.

Article  PubMed  PubMed Central  Google Scholar 

Miller TP, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21–6.

Article  CAS  PubMed  Google Scholar 

Persky DO, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26(14):2258–63.

Article  CAS  PubMed  Google Scholar 

Pfreundschuh M, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91.

Article  CAS  PubMed  Google Scholar 

Poeschel V, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271–81.

Article  CAS  PubMed  Google Scholar 

Tilly H, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386(4):351–63.

Article  CAS  PubMed  Google Scholar 

Horning SJ, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol. 2004;22(15):3032–8.

Article  CAS  PubMed  Google Scholar 

Held G, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32(11):1112–8.

Article  PubMed  Google Scholar 

Vargo JA, et al. Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: do we still need consolidative radiotherapy? J Clin Oncol. 2015;33(32):3710–7.

Article  CAS  PubMed  Google Scholar 

Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.

Article  CAS  PubMed  Google Scholar 

Yuan T, et al. Maintenance therapy for untreated diffuse large B-cell lymphoma: a systematic review and network meta-analysis. Ther Adv Hematol. 2021;12:20406207211018896.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berger MD, et al. Impact on survival through consolidation radiotherapy for diffuse large B-cell lymphoma: a comprehensive meta-analysis. Haematologica. 2021;106(7):1923–31.

Article  CAS  PubMed  Google Scholar 

Stiff PJ, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Philip T, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333(23):1540–5.

Article  CAS  PubMed  Google Scholar 

Locke FL, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386(7):640–54.

Article  CAS  PubMed  Google Scholar 

Kamdar M, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–308.

Article  CAS  PubMed  Google Scholar 

Gisselbrecht C, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–90.

Article  PubMed  PubMed Central  Google Scholar 

Mey UJ, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvae treatment for patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma. Cancer Invest. 2006;24(6):593–600.

Article  CAS  PubMed  Google Scholar 

Martín A, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica. 2008;93(12):1829–36.

Article  PubMed  Google Scholar 

Kewalramani T, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004;103(10):3684–8.

Article  CAS  PubMed  Google Scholar 

Oki Y, et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Cancer Sci. 2008;99(1):179–84.

Article  CAS  PubMed  Google Scholar 

Jermann M, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol. 2004;15(3):511–6.

Article  CAS  PubMed  Google Scholar 

Rodriguez MA, et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995;6(6):609–11.